(Q43072014)

13 November 2017

Evaluation of Ki-67 and Bcl-2 antigen expression in breast carcinomas of women treated with raloxifene (English)

1 reference

13 November 2017

P V Lopes-Costa

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496800&resulttype=core&format=json

14 May 2020

A R dos Santos

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496800&resulttype=core&format=json

14 May 2020

L G dos Santos

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496800&resulttype=core&format=json

14 May 2020

B B da Silva

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496800&resulttype=core&format=json

14 May 2020

language of work or name

1 reference

1 April 2010

1 reference

13 November 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496800&resulttype=core&format=json

14 May 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496800&resulttype=core&format=json

14 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496800&resulttype=core&format=json

14 May 2020

page(s)

124-129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496800&resulttype=core&format=json

Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.

14 May 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2009.00664.X

Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2009.00664.X

Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

21 January 2018

1 reference

12 December 2020

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

12 December 2020

Paradoxical inhibition of solid tumor cell growth by bcl2

1 reference

12 December 2020

Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death.

1 reference

12 December 2020

Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women

1 reference

12 December 2020

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

1 reference

12 December 2020

Integrated control of cell proliferation and cell death by the c-myc oncogene

1 reference

12 December 2020

Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer

1 reference

12 December 2020

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

12 December 2020

Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor?

1 reference

12 December 2020

Bcl-2 oncogene expression in estrogen receptor-positive and negative breast carcinoma.

1 reference

12 December 2020

Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value

1 reference

12 December 2020

Application of selective estrogen receptor modulators for breast cancer treatment according to their intrinsic nature

1 reference

12 December 2020

Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response

1 reference

12 December 2020

Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer

1 reference

12 December 2020

Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen

1 reference

12 December 2020

Tamoxifen: important considerations of a multi-functional compound with organ-specific properties

1 reference

12 December 2020

Apoptotic index in breast carcinoma cells following tamoxifen treatment

1 reference

12 December 2020

Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients

1 reference

12 December 2020

The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.

1 reference

12 December 2020

Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk

1 reference

12 December 2020

Effects of raloxifene on Ki-67 and CD34 antigen expression in breast cancer

1 reference

12 December 2020

Safety assessment of raloxifene over eight years in a clinical trial setting

1 reference

12 December 2020

10.1111/J.1365-2184.2009.00664.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496800&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496800&resulttype=core&format=json

14 May 2020

1 reference